As the fourth medicine for Risk-sharing, 'Xtandi soft capsule (enzalutamide)' is likely to be selected
As the fourth medicine for Risk-sharing, Astellas Pharmaceutical's prostate cancer treatment 'Xtandi soft capsule (enzalutamide)' is likely to be selected.
On July 10, it was known that Health Insurance Review and Assessment Service evaluated Xtandi suitable for the condition of risk sharing on ...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
